ArticleClinical journal of the American Society of Nephrology : CJASN2012
Antibodies against linear epitopes on the Goodpasture autoantigen and kidney injury.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- IgA nephropathy shortly follwed by seroconversion of positive anti-GBM antibodies and rapid progressive glomerulonephritis in a Chinese boy: coincidental overlap or pathogenic link?BMC nephrology · 2026Article
- Butyric Acid-Modified m-P14 Peptide Ameliorates Anti-Glomerular Basement Membrane Disease.International journal of molecular sciences · 2026Article
- Identification of antibodies against phospholipase A2 receptor peptides in PLA2R-associated membranous nephropathy with negative circulating anti-PLA2R antibodies.Frontiers in immunology · 2026Article
- Review
- Atypical anti-glomerular basement membrane disease complicated by methicillin-susceptible Staphylococcus aureus infection-related rapidly progressive glomerulonephritis: a case report and literature review.CEN case reports · 2021Review
- Experimental Antiglomerular Basement Membrane GN Induced by a Peptide fromJournal of the American Society of Nephrology : JASN · 2020Article
- Goodpasture's autoimmune disease - A collagen IV disorder.Matrix biology : journal of the International Society for Matrix Biology · 2018Review
- A New Classification System for IgG4 Autoantibodies.Frontiers in immunology · 2018Review
- The pathogenicity of T cell epitopes on human Goodpasture antigen and its critical amino acid motif.Journal of cellular and molecular medicine · 2017Article
- Antibodies against linear epitopes on Goodpasture autoantigen in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.Clinical rheumatology · 2017Article
- Clinicopathological characteristics of typical and atypical anti-glomerular basement membrane nephritis.Journal of nephrology · 2017Review
- The susceptible HLA class II alleles and their presenting epitope(s) in Goodpasture's disease.Immunology · 2017Article
- Plasma from patients with anti-glomerular basement membrane disease could recognize microbial peptides.PloS one · 2017Article
- Autoantibodies against Linear Epitopes of Myeloperoxidase in Anti-Glomerular Basement Membrane Disease.Clinical journal of the American Society of Nephrology : CJASN · 2016Article
- Article
- Identification of critical residues of linear B cell epitope on Goodpasture autoantigen.PloS one · 2015Article
- Vasculitis: determinants of disease patterns.Nature reviews. Rheumatology · 2014Review
- Principles of separation: indications and therapeutic targets for plasma exchange.Clinical journal of the American Society of Nephrology : CJASN · 2014Review
- Characteristics and outcome of crescentic glomerulonephritis in patients with both antineutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody.Clinical rheumatology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesLinear epitopes on the Goodpasture autoantigen involved in human anti-glomerular basement membrane (GBM) disease are not fully defined. This study investigated the linear epitopes recognized by circulating antibodies in anti-GBM patients, aiming to identify the potential nephrogenic linear epitopes and their clinical significance. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Sixty-eight patients with anti-GBM disease were enrolled. Twenty-four overlapping linear peptides were synthesized across the whole sequence of the human Goodpasture autoantigen. ELISA detected circulating antibodies against linear epitopes. Their associations with clinical features were further analyzed.
resultsAntibodies against linear peptides were detected in sera from 55 patients (80.9%). Three major epitopes with high frequencies were identified: P14 (41%), P16 (36.8%), and P18 (57%). P14, a formerly defined T cell epitope, was a mutual B cell epitope. Antibodies against P14 were frequently detected in patients with positive antineutrophil cytoplasmic antibodies (39.3% versus 12.5%; P=0.01). Patients with anti-P16 antibodies presented with higher serum creatinine on diagnosis (665.5±227.2 versus 443.7±296.8 μmol/L; P=0.001) and worse renal outcome during follow-up (hazard ratio, 2.10; 95% confidence interval, 1.10-3.90; P=0.02). The level of anti-P18 antibodies positively correlated with the percentage of crescents in glomeruli (r=0.54; P=0.008). Recognition of P22 was an independent predictor for patient death (hazard ratio, 3.02; 95% confidence interval, 1.20-7.57; P=0.02).
conclusionsAntibodies against linear epitopes on the Goodpasture autoantigen could be detected in human anti-GBM disease and were associated with kidney injury. P14 was a mutual T and B cell epitope, implying its nephrogenic role in disease initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.